The Part D Senior Savings Model could lower beneficiary out-of-pocket costs next year while allowing us to assess the impact of this change on overall medical spending and health outcomes.

The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.

Key Takeaways. Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply ...

Dive Brief: CMS on Monday unveiled a new model for Medicare Part D to test lowering out-of-pocket insulin costs for diabetics on some of the privately run prescription drug plans.; The voluntary ...

At the same time, many Medicare beneficiaries are likely to see reductions in their PrEP out-of-pocket costs with the implementation of a $2,000 annual Part D out-of-pocket maximum in combination ...

Patients with insurance who paid out-of-pocket for deductibles or amounts due after insurance have dropped over 20 percent in the past year, standing at only 55 percent down from 76 percent in 2021.

For specialty-drug users in the 95th percentile of specialty-drug out-of-pocket spending overall (evaluating all three intervention states and years together), caps were associated with a change ...